Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR0521)
Drug Name
SC-411
Synonyms
AquaGrow Advantage; Cervonic acid; Doconexent; Doconexento; Doconexentum; Docosahexaenoate; Docosahexaenoic acid; Docosahexaenoic acid (all-Z); Doxonexent; Martek DHA HM; Ropufa 60; ZAD9OKH9JC; all-Z-Docosahexaenoic acid; (4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid; (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid; 6217-54-5; CCRIS 7670; CHEMBL367149; UNII-ZAD9OKH9JC; all-cis-4,7,10,13,16,19-Docosahexaenoic acid; all-cis-DHA; all-cis-docosa-4,7,10,13,16,19-hexaenoic acid; cis-4,7,10,13,16,19-Docosahexaenoic acid
Indication Alzheimer disease [ICD11: 8A20] Phase 3 [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 328.5 Topological Polar Surface Area 37.3
Heavy Atom Count 24 Rotatable Bond Count 14
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 2
Cross-matching ID
PubChem CID
445580
PubChem SID
8664 ; 839059 ; 841847 ; 7850049 ; 8144392 ; 10299728 ; 14924254 ; 24893696 ; 26754926 ; 26754927 ; 26754928 ; 36888254 ; 46391883 ; 47515089 ; 47515090 ; 47885165 ; 48184752 ; 50110834 ; 50110835 ; 57404690 ; 75281905 ; 81063745 ; 85787686 ; 87568664 ; 91695933 ; 92165132 ; 92298371 ; 92309714 ; 92719165 ; 99300628 ; 99302146 ; 103445456 ; 104046523 ; 104086818 ; 104179148 ; 104634620 ; 118048648 ; 126524415 ; 126621028 ; 126655302 ; 134350834 ; 135028589 ; 135651477 ; 137003172 ; 142339426 ; 144205545 ; 152101578 ; 162180738 ; 162227670 ; 163659264
ChEBI ID
CHEBI:28125
CAS Number
6217-54-5
TTD Drug ID
D0Q5XX
Formula
C22H32O2
Canonical SMILES
CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)O
InChI
1S/C22H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24/h3-4,6-7,9-10,12-13,15-16,18-19H,2,5,8,11,14,17,20-21H2,1H3,(H,23,24)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-
InChIKey
MBMBGCFOFBJSGT-KUBAVDMBSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
10,11-EDP DM005994
11638767
Unclear 1 [2]
19,20-epoxydocosapentaenoic acid DM005993
35020807
Oxidation - 10-epoxidation 1 [2]
21,22-HDoHE DM005995 N. A. Unclear 1 [2]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR006452 SC-411 19,20-epoxydocosapentaenoic acid Oxidation - 10-epoxidation CYP2J2 [2]
MR006453 SC-411 10,11-EDP Unclear CYP2C9 [2]
MR006454 SC-411 21,22-HDoHE Unclear CYP4A11 [2]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 2C9 (CYP2C9) DME0019 Homo sapiens
CP2C9_HUMAN
1.14.14.1
[2]
Cytochrome P450 2J2 (CYP2J2) DME0031 Homo sapiens
CP2J2_HUMAN
1.14.14.24
[2]
Lauric acid omega-hydroxylase (CYP4A11) DME0029 Homo sapiens
CP4AB_HUMAN
1.14.15.3
[2]
Prostaglandin G/H synthase 1 (COX-1) DME0091 Homo sapiens
PGH1_HUMAN
1.14.99.1
[3]
Prostaglandin G/H synthase 2 (COX-2) DME0114 Homo sapiens
PGH2_HUMAN
1.14.99.1
[3]
Experimental Enzyme Kinetic Data of This Drug
DME Name DME Info Kinetic Data Uniprot ID REF
Prostaglandin G/H synthase 1 (COX-1) DME0091 Km = 0.0011 microM
PGH1_HUMAN
[3]
Prostaglandin G/H synthase 2 (COX-2) DME0114 Km = 0.0011 microM
PGH2_HUMAN
[3]
References
1 ClinicalTrials.gov (NCT00069784) The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention).
2 CYP-eicosanoids--a new link between omega-3 fatty acids and cardiac disease? Prostaglandins Other Lipid Mediat. 2011 Nov;96(1-4):99-108.
3 Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.